NMN for Cardiovascular Health After 50: What the Research Shows

Cardiovascular Health Guide · Updated June 2026

Cardiovascular disease is Australia's leading cause of death and a primary health concern for most Australians over 50. The Australian Institute of Health and Welfare documents that heart disease kills one Australian every 12 minutes. For men and women navigating the post-50 cardiac risk landscape, any supplement with potential cardiovascular relevance warrants honest, evidence-based assessment.

NAD+ depletion is increasingly recognised in cardiovascular research as contributing to vascular and cardiac ageing. This guide covers what the current evidence shows — and is explicit about where the evidence is limited.

NAD+ and Cardiac Function: The Cellular Mechanism

Heart muscle cells (cardiomyocytes) are among the most energy-intensive cells in the body — the heart never stops, and its constant rhythmic contraction requires enormous, continuous ATP production. Cardiomyocytes are consequently among the most NAD+-dependent cells in the body.

As NAD+ declines with age, cardiomyocyte mitochondrial efficiency declines. Research in animal models has documented that cardiac NAD+ levels fall significantly with age, and that this decline is associated with impaired cardiac energy metabolism and reduced heart function. Restoring NAD+ in aged animal models improves cardiac mitochondrial function and stress tolerance.

Human evidence for cardiac NAD+ restoration is more limited. No published human RCT has specifically tested NMN as a cardiovascular intervention. What exists is mechanistic evidence, animal model data, and the general human NAD+ elevation evidence from NMN trials — with extrapolation to cardiovascular tissue.

Vascular Effects: Endothelium and Blood Pressure

The endothelium — the inner lining of blood vessels — depends on NAD+ for SIRT1-mediated nitric oxide production and vascular inflammation control. NAD+ depletion impairs endothelial function, contributing to vascular stiffness and reduced blood pressure regulation capacity.

Some research suggests NMN may modestly reduce blood pressure through improved endothelial NAD+ availability and SIRT1 activation. This is the mechanism behind the note in our safety guide about discussing NMN with your GP if you are on antihypertensives — not because NMN is dangerous, but because the combined blood pressure reduction could be meaningful.

Pterostilbene and LDL Cholesterol

Pterostilbene — included at 120mg per serving in Nadovia's Longevity Complex — has direct human evidence for LDL cholesterol reduction. A randomised clinical trial found Pterostilbene at 100mg daily reduced total cholesterol and LDL in hypercholesterolaemic adults over 12 weeks. For Australian adults over 50 managing lipid profiles, this is a meaningful secondary benefit from the formula.

Pterostilbene's mechanism is through PPAR-α activation — the same transcription factor that statins engage, though through a different pathway and at a much smaller magnitude. It is not a statin replacement. It is a complementary lipid-management mechanism with good tolerability.

Quercetin and Cardiovascular Inflammation

Quercetin — included at 300mg per serving — has substantial human evidence for anti-inflammatory cardiovascular effects. It inhibits NF-κB (reducing vascular inflammation), reduces oxidised LDL levels, and has evidence for modest blood pressure reduction through endothelial mechanisms. The Quercetin component of Nadovia's formula is the ingredient with the most directly documented cardiovascular evidence.

What NMN Does Not Replace

This section matters for Australians with diagnosed cardiovascular conditions or elevated cardiac risk:

• Statins: If prescribed, NMN does not replace statin therapy. Pterostilbene provides complementary LDL benefit at a much smaller magnitude. Discuss combining with your GP.
• Antihypertensives: If prescribed, monitor blood pressure when adding NMN — potential additive effect on blood pressure reduction.
• Blood thinners: Resveratrol in the formula has mild antiplatelet properties — discuss with your prescriber.
• Cardiac rehabilitation: Exercise, diet, and medical management remain the primary evidence-based cardiovascular interventions. Heart Foundation Australia provides evidence-based guidance.

FAQ

References: Boslett J et al., Circulation Research (2018) — cardiac NAD+; Krikorian R et al., J Agric Food Chem (2010) — Pterostilbene LDL; heartfoundation.org.au; AIHW CVD statistics. Not medical advice — consult your cardiologist for cardiac management.